Overview

Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

This phase II trial studies the side effects and best dose of niraparib, and to see how well it works in combination with standard of care radiation therapy and hormonal therapy (androgen deprivation therapy) in treating patients with prostate cancer that has a high chance of coming back (high risk). Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Adding niraparib to the usual treatments of radiation therapy and hormonal therapy may lower the chance of prostate cancer growing or returning.

Phase:

Phase 2

Details

Lead Sponsor:

NRG Oncology

Collaborator:

National Cancer Institute (NCI)

Treatments:

Androgens
Follicle Stimulating Hormone
Hormones
Niraparib
Prolactin Release-Inhibiting Factors